在B细胞中对伊诺图祖马布臭胺素的反应和耐药性的基因组决定因素ALL
Yaqi Zhao1,2, Nicholas J Short3, Hagop M Kantarjian3
1Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN.
Blood
|March 29, 2024
概括
在B细胞急性淋巴细胞白血病中,伊诺图祖马布对奥佐加米辛的耐药性与CD22突变和DNA修复改变有关. 了解这些基因组变化是改善CD22向治疗和克服治疗耐药性的关键.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 免疫治疗是一种免疫疗法.
背景情况:
- 伊诺图祖马布 (Inotuzumab ozogamicin) 向B细胞急性淋巴细胞白血病 (B-ALL) 中的CD22表达细胞.
- 了解影响INO反应和耐药性的基因组因素对于优化治疗策略至关重要.
研究的目的:
- 研究B-ALL患者对InO的反应和耐药性的基因组决定因素.
- 为了确定CD22逃逸和治疗耐药性的机制.
主要方法:
- 在InO治疗前和后的患者样本的回顾性分析.
- 整个基因组,外基因组和转录基因组的测序.
- 在细胞系中进行全基因组的CRISPR/Cas9选.
主要成果:
- 在复发的,但不耐火的样本中观察到赋予耐药性的获得的CD22突变.
- CD22逃逸的机制包括表位损失和改变,有些病例表现出高突变.
- 在TP53,ATM和CDKN2A的功能丧失突变与逃避INO诱导的亡有关.
- DNTT 损失被确定为 InO 耐药性的标记.
结论:
- CD22和DNA损伤反应途径的遗传变化显著影响了InO的疗效.
- 识别CD22逃生机制对于改善治疗方法和在HSCT之前根除残留疾病至关重要.
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K


